Healthcare -
Biotechnology - NASDAQ - US
$ 4.7
-15.6 %
$ 535 M
Market Cap
-2.42
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Cogent Biosciences, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 276 M |
| Operating Income | -276 M |
| Other Expenses | -20.1 M |
| Net Income | -256 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 7.9 | 22.5 | 9.7 | 8.4 | 6.4 | 3.0 |
| GROSS PROFIT | ||||||||||
| Cost Of Revenue | 0 | 3.6 | 5.9 | 0.1 | 25.7 K | 43.7 K | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | (3.6) | (5.9) | (0.1) | 7.8 | 22.5 | 9.7 | 8.4 | 6.4 | 3.0 |
| OPERATING INCOME | ||||||||||
| Operating Expenses | 275.9 | 208.1 | 147.8 | 75.6 | 90.1 | 54.7 | 45.7 | 34.5 | 25.4 | 9.6 |
| Selling, General and Administrative Expenses | 43.3 | 34.4 | 26.2 | 19.6 | 17.4 | 11.0 | 7.5 | 4.7 | 3.4 | 2.7 |
| Research and Development Expenses | 232.7 | 170.2 | 121.6 | 55.9 | 72.6 | 43.7 | 38.3 | 29.8 | 22.0 | 6.9 |
| Operating Income | (275.9) | (208.1) | (147.8) | (75.6) | (82.2) | (32.2) | (36.0) | (26.2) | (19.1) | (6.6) |
| PRE-TAX INCOME | ||||||||||
| Interest Income Expense | 0 | 0 | 4.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 20.1 | 15.7 | 7.6 | 3.3 | 7.4 | 0.3 | 1.5 | 0.7 | 0.9 | 0 |
| Pre-Tax Income | (255.9) | (192.4) | (140.2) | (72.3) | (74.8) | (31.8) | (34.5) | (25.5) | (18.1) | (6.6) |
| NET INCOME | ||||||||||
| Tax Provision | 0 | 0 | (7.6) | (0.5) | (8.4) | (1.6) | 1.5 | (0.4) | (0.3) | 0 |
| Net Income | (255.9) | (192.4) | (132.6) | (71.8) | (66.5) | (30.3) | (34.5) | (25.5) | (18.1) | (6.6) |
| EPS | 3.49 | 2.42 | 2.26 | 1.85 | 6 | 3.97 | 5.55 | 3.45 | 3.1 | 1.13 |